Literature DB >> 7686838

Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.

J C Gris1, J F Schved, C Marty-Double, J M Mauboussin, P Balmes.   

Abstract

STUDY
OBJECTIVE: To compare the expression of plasminogen activators (PA) and plasminogen activator inhibitors (PAI) in normal lung mucosa and lung carcinomas.
DESIGN: Immunohistochemical localization of urokinase-type PA (uPA), tissue-type PA (tPA), type 1 PAI (PAI-1), and type 2 PAI (PAI-2) in four normal lung biopsy specimens and in four adenocarcinomas (AC), four squamous carcinomas (SC), two large-cell carcinomas (LCC), and ten small-cell carcinomas (SCC) biopsy specimens. Qualitative immunostaining scoring system.
RESULTS: tPA and uPA immunostaining scores from all specimens were statistically similar. The cellular staining for uPA and tPA was generally constant (normal epithelial layers, AC cells, SC cells) except for LCC cells (inconstant uPA staining, p < 10(-3). Both PAIs were detected in cells of the normal epithelial layer. The four carcinoma cell types stained for PAI in a statistically different pattern (p < 10(-3)). Cells of the peripheral cords of SCC were inconstantly PAI-1 and PAI-2 positive (p < 10(-3)). LCC were PAI-2 negative and inconstantly stained for PAI-1. SCC cells were PAI-1 and PAI-2 negative.
CONCLUSION: Lung carcinomas of worst clinical prognosis no longer express PAI reactivity. The imbalance of the plasminogen activation pathway may favor the spreading of the more invasive histologic types of bronchogenic carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686838     DOI: 10.1378/chest.104.1.8

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas.

Authors:  Maria Ramnefjell; Christina Aamelfot; Lars Helgeland; Lars A Akslen
Journal:  Oncotarget       Date:  2017-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.